Pfizer (PFE) scored the top spot in Interbrand Health's inaugural ranking of the top ten biopharmaceutical brands. The ranking uses analytics to quantify the measurable, financial impact that a company's brand has on its overall business performance. After Pfizer, the top ranked brands in order were Roche/Genentech, Merck/MSD (MRK) , Johnson & Johnson's (JNJ) Janssen unit, Novartis (NVS) , Amgen (AMGN) , Gilead (GILD) , Novo Nordisk, AstraZeneca (AZN) , and GSK (GSK) . InterbrandHealth said corporate branding is an undervalued asset, and the Best Pharma Brands report demonstrates how a company's corporate brand influences decisions made by health care providers.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.